Jublia

Faced with $30 billion in debt, Valeant Pharmaceuticals Intl Inc (NYSE: VRX) has few options at its disposal. Among the company's options to reduce its debt load includes selling off some of its drug assets, or selling complete business units. According to a report by Reuters, Valeant is...

In a report published Monday, Canaccord Genuity analyst Neil Maruoka commented that Valeant Pharmaceuticals Intl Inc (NYSE: VRX) is "firing on all cylinders." Valeant On Fire Maruoka noted the company's strong fourth-quarter report that showed a "robust" base business...